SEC Company Response from PDS Biotechnology Corp (PDSB) (CIK 0001472091) (PDSB) — Nov 1, 2016
PDS Biotechnology Corp (PDSB) (CIK 0001472091)
Date: Nov. 1, 2016 · CIK: 0001472091 · Accession: 0001567619-16-003146
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-214196
Letter
RE:
November 1, 2016
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC 20549
Attention: Suzanne Hayes, Assistant Director
Edge Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-214196
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Edge Therapeutics, Inc. hereby requests, subject to telephone confirmation, that the effectiveness of the above-captioned Registration Statement be accelerated so that it will become effective as of 2:00 p.m. EST on November 2, 2016, or as soon thereafter as practicable.
Very truly yours,
EDGE THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm November 1, 2016 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Suzanne Hayes, Assistant Director RE: Edge Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-214196 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Edge Therapeutics, Inc. hereby requests, subject to telephone confirmation, that the effectiveness of the above-captioned Registration Statement be accelerated so that it will become effective as of 2:00 p.m. EST on November 2, 2016, or as soon thereafter as practicable. Very truly yours, EDGE THERAPEUTICS, INC. /s/ Andrew J. Einhorn Andrew J. Einhorn Chief Financial Officer